InternationalUSRemember you can easily switch between MIP US and MIP International at any time

In-house roundup: 5G licensing challenges; second medical use solutions; PTAB tactics against NPEs; dosage regimen inventive step



Patrick Wingrove, London


Managing IP rounds up the latest news and analysis from patent-focused businesses on 5G, the PTAB, inventive step and second medical use reform

effbdf

5G set to exacerbate FRAND problems, say top patent holders 

With more diverse non-telecoms businesses using 5G tech, licensing discussions for standard essential patents are likely to increase and become more difficult to negotiate, leading patentees to promote better licensing education. Read More... 

Prescription reform needed to avoid second medical use infringement 

Generic and innovator in-house lawyers agree that serious reform to the way medications are prescribed is needed to avoid patent infringement on secondary uses, and that they will need to work together to make that change.
Read more... 

How tech companies use the PTAB to fight patent trolls 

Senior sources from high-tech, gaming and financial services companies explain how they succeed in their inter partes reviews and covered business method actions to invalidate broad patents filed by non-practising entities. Read more... 

Inventive step: pharma innovators say "routine testing is never routine" 

After the UK Supreme Court's ruling in Acatvis v Icos, pharma innovators say there is no such thing as routine testing and that it is difficult to discern what might be considered obvious in dosage regimens. Read more... 

Sign up to receive more content like this in Patent Strategy’s weekly newsletter.



Comments






More from the Managing IP blog


null null null

nullnullnull

null

May / June 2019

From trademarks to trade secrets: in-house tips on brand protection in China

Despite the well-known struggles in protecting trademarks and trade secrets in China, there are some tried-and-tested strategies to employ, as Karry Lai and Ellie Mertens hear from in-house counsel at a range of domestic and international companies



Most read articles

Supplements